Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety.

Unterweger H, Dézsi L, Matuszak J, Janko C, Poettler M, Jordan J, Bäuerle T, Szebeni J, Fey T, Boccaccini AR, Alexiou C, Cicha I.

Int J Nanomedicine. 2018 Mar 28;13:1899-1915. doi: 10.2147/IJN.S156528. eCollection 2018.


Toxicity of Mitoxantrone-loaded Superparamagnetic Iron Oxide Nanoparticles in a HT-29 Tumour Spheroid Model.

Hornung A, Poettler M, Friedrich RP, Weigel B, Duerr S, Zaloga J, Cicha I, Alexiou C, Janko C.

Anticancer Res. 2016 Jun;36(6):3093-101.


Hypericin-bearing magnetic iron oxide nanoparticles for selective drug delivery in photodynamic therapy.

Unterweger H, Subatzus D, Tietze R, Janko C, Poettler M, Stiegelschmitt A, Schuster M, Maake C, Boccaccini AR, Alexiou C.

Int J Nanomedicine. 2015 Nov 12;10:6985-96. doi: 10.2147/IJN.S92336. eCollection 2015.


Nanomedical innovation: the SEON-concept for an improved cancer therapy with magnetic nanoparticles.

Lyer S, Tietze R, Unterweger H, Zaloga J, Singh R, Matuszak J, Poettler M, Friedrich RP, Duerr S, Cicha I, Janko C, Alexiou C.

Nanomedicine (Lond). 2015;10(21):3287-304. doi: 10.2217/nnm.15.159. Epub 2015 Oct 16.


Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids.

Hornung A, Poettler M, Friedrich RP, Zaloga J, Unterweger H, Lyer S, Nowak J, Odenbach S, Alexiou C, Janko C.

Molecules. 2015 Sep 30;20(10):18016-30. doi: 10.3390/molecules201018016.


Effects of cilengitide in osteoclast maturation and behavior.

Chillà A, Bianconi D, Geetha N, Dorda A, Poettler M, Unseld M, Sykoutri D, Redlich K, Zielinski CC, Prager GW.

Exp Cell Res. 2015 Sep 10;337(1):68-75. doi: 10.1016/j.yexcr.2015.07.018. Epub 2015 Jul 21.


Flow cytometry for intracellular SPION quantification: specificity and sensitivity in comparison with spectroscopic methods.

Friedrich RP, Janko C, Poettler M, Tripal P, Zaloga J, Cicha I, Dürr S, Nowak J, Odenbach S, Slabu I, Liebl M, Trahms L, Stapf M, Hilger I, Lyer S, Alexiou C.

Int J Nanomedicine. 2015 Jun 26;10:4185-201. doi: 10.2147/IJN.S82714. eCollection 2015.


CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior.

Poettler M, Unseld M, Braemswig K, Haitel A, Zielinski CC, Prager GW.

Mol Cancer. 2013 Dec 21;12:169. doi: 10.1186/1476-4598-12-169.


Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis.

Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, Zielinski CC, Prager GW.

Cancer Res. 2013 Nov 15;73(22):6584-96. doi: 10.1158/0008-5472.CAN-13-0123. Epub 2013 Oct 11.


The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration.

Poettler M, Unseld M, Mihaly-Bison J, Uhrin P, Koban F, Binder BR, Zielinski CC, Prager GW.

Thromb Haemost. 2012 Aug;108(2):357-66. doi: 10.1160/TH11-12-0868. Epub 2012 Jul 10.


Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Prager GW, Poettler M, Unseld M, Zielinski CC.

Transl Lung Cancer Res. 2012 Mar;1(1):14-25. doi: 10.3978/j.issn.2218-6751.2011.11.02. Review.


Angiogenesis in cancer. Basic mechanisms and therapeutic advances.

Prager GW, Poettler M.

Hamostaseologie. 2012;32(2):105-14. doi: 10.5482/ha-1163. Epub 2011 Aug 12. Review.


Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.

Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, Cerny-Reiterer S, Lamm W, Kornek GV, Binder BR, Zielinski CC, Valent P.

Mol Oncol. 2010 Apr;4(2):150-60. doi: 10.1016/j.molonc.2010.01.002. Epub 2010 Jan 7.


CD98hc (SLC3A2), a novel marker in renal cell cancer.

Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC, Haitel A.

Eur J Clin Invest. 2009 Apr;39(4):304-10. doi: 10.1111/j.1365-2362.2009.02096.x.


Supplemental Content

Loading ...
Support Center